Global Expansion of TAVR Vision

Jiecheng College was co-founded by Jiecheng Medical and many surgical experts across the country. It has continuously provided exclusive, practical and advanced education to physicians in various fields, and has become a highly popular professional TAVR training college. Jiecheng College is committed to allowing more experts to spread and improve their excellent foreign science and technology skills across the world, granting doctors with different experiences in different regions the best educational resources to help expand TAVR globally.

Product Introduction

J-Valve®series

Transapical implant

The short transmission path integrates excellent human factors engineering design, four digital control keys, easy to obtain the best coaxiality, short learning curve

Learn more

Transcatheter Apical Implant

　　The "Precision Positioning Heart Valve Implantation System" is a minimally invasive surgical technique that does not require chest opening or extracorporeal blood circulation, which can significantly reduce the surgical trauma, shorten the postoperative recovery time, reduce the patient's pain, and lower the requirements for the patient's physical condition, thus expanding the scope of application, improving the treatment effect, and reducing the cost of surgery. This will allow the majority of patients who need heart valve replacement to be treated. This technology will change the traditional surgical approach, making it easier to perform and master, simplifying the heart valve replacement process and reducing the demands on the surgeon. While other similar products require imaging technology to implant the valve into the human heart, the Suzhou Jie Cheng product can rely entirely on the implantation system's own positioning device to complete the valve replacement surgery, thereby reducing the risk of surgery and allowing patients to receive timely treatment.

J-Valve Heart Valve

Approved by NMPA, it can effectively treat severe aortic regurgitation (insufficiency) and stenosis at the same time as an interventional bioprosthetic heart valve product

Learn more

J-Valve Heart Valve

The "Precision Positioning Heart Valve Implantation System" is a minimally invasive surgical technique that does not require chest opening or extracorporeal blood circulation, which can significantly reduce the surgical trauma, shorten the postoperative recovery time, reduce the patient's pain, and lower the requirements for the patient's physical condition, thus expanding the scope of application, improving the treatment effect, and reducing the cost of surgery. This will allow the majority of patients who need heart valve replacement to be treated. This technology will change the traditional surgical approach, making it easier to perform and master, simplifying the heart valve replacement process and reducing the demands on the surgeon. While other similar products require imaging technology to implant the valve into the human heart, the Suzhou Jie Cheng product can rely entirely on the implantation system's own positioning device to complete the valve replacement surgery, thereby reducing the risk of surgery and allowing patients to receive timely treatment.

About JC Medical

Suzhou Jiecheng Medical Technology Co., Ltd. was established in September 2009. It is a high-tech enterprise focusing on the R&D and manufacturing of high-end cardiovascular medical devices. It has a number of international PCT invention patents, and its innovative technology is in the leading position in the world.

3000 +

Cumulative number of cases in Mainland China
20 +

Cumulative number of cases in Hong Kong
10 +

Cumulative number of cases in Taiwan
160 +

Cooperate with the top cardiovascular surgery hospitals in the country
10 +

Global patents

JC Information

2021 05-07

[Academic Reprint] Largest sample size! Huaxi Hospital Team Publishes Research Results on TAVR for Aortic Valve Regurgitation

Aortic regurgitation encompasses a complex array of pathophysiologic mechanisms. According to the literature, the percentage of the general population with severe aortic regurgitation is approximately 1%. The average life expectancy of this group is only about 5 years from the time of diagnosis of the disease. As of today, surgical aortic valve replacement (SAVR) remains the mainstay of treatment for severe aortic regurgitation, while patients at very high risk for surgical procedures or with significant contraindications are usually treated conservatively.

See more information